|
Formaldehyde Catalysis of Nitrosamine Formation
|
|
3
|
643
|
May 31, 2024
|
|
⚙️🌎CPCA: the gestation, birth, and development -Pub
|
|
5
|
1168
|
May 31, 2024
|
|
Genotoxicity assessments of N-nitrosoethylisopropylamine (NEIPA) and N-nitrosodiisopropylamine (NDIPA) in the C57BL/6J mouse -Pub
|
|
0
|
301
|
May 13, 2024
|
|
Nitrosamines: A new systematic review
|
|
8
|
3164
|
April 13, 2024
|
|
SOT posters and talks, (shared posters -update)
|
|
3
|
847
|
April 10, 2024
|
|
1st release of Lhasa 'Complex Nitrosamines' data sharing initiative
|
|
6
|
1077
|
March 31, 2024
|
|
Antioxidant as a risk mitigation strategy
|
|
5
|
764
|
March 28, 2024
|
|
Acceptable Intakes (AIs) for 11 Small molecule N-nitrosamines (NAs) -Pub
|
|
17
|
2756
|
March 28, 2024
|
|
Lack of effect of antioxidants on Biopharmaceutics Classification System (BCS) Class III drug permeability -Pub
|
|
1
|
514
|
March 13, 2024
|
|
Role of Carbonyl Compounds for N-Nitrosamine Formation during Nitrosation: Kinetics and Mechanisms
|
|
0
|
413
|
March 2, 2024
|
|
In Silico Prediction of Pharmaceutical Degradation Pathways: A Benchmarking Study Using the Software Program Zeneth
|
|
3
|
430
|
February 24, 2024
|
|
In Silico Prediction of N-Nitrosamine Formation Pathways of Pharmaceutical Products -Pub
|
|
0
|
538
|
February 8, 2024
|
|
Metabolic activation of short-chain alkyl N-nitrosamines using Aroclor 1254 or phenobarbital/beta-naphthoflavone-induced rat or hamster S9 – a comparative analysis -Pub
|
|
4
|
463
|
February 2, 2024
|
|
📚 OPRD Special Issue on Nitrosamines -Pub
|
|
13
|
2479
|
January 23, 2024
|
|
Formation of N-Nitrosamines by Reaction of Secondary Dialkylamines with Trace Levels of Nitrite in Aqueous Solution: An Automated Experimental and Kinetic Modeling Study Using Di-n-butylamine
|
|
2
|
1116
|
December 30, 2023
|
|
N-nitrosamines considerations for Inhalation products
|
|
10
|
1103
|
December 24, 2023
|
|
N- NITROSO DESMETHYL LOPERAMIDE is it possible?
|
|
4
|
577
|
December 18, 2023
|
|
Redefining Nitrosamine Risks: A Fresh Perspective on Pharmaceuticals -Pub
|
|
16
|
2446
|
December 17, 2023
|
|
New data released into Lhasa Carcinogenicity Database
|
|
1
|
1005
|
November 17, 2023
|
|
Why do some mutagenic N-nitrosamines not require metabolic activation?
|
|
0
|
400
|
November 15, 2023
|
|
Review of NDSRIs in Pharmaceutical Drugs -Pub
|
|
1
|
901
|
November 13, 2023
|
|
Does atmospheric NO2 influence the formation of NDMA in metformin?
|
|
2
|
616
|
November 3, 2023
|
|
Not all Nitro structures are Nitrosamines!
|
|
1
|
862
|
November 2, 2023
|
|
Developing Structure-Activity Relationships for N-Nitrosamine Activity
|
|
7
|
653
|
October 13, 2023
|
|
Nitrosamines in Biologics
|
|
1
|
678
|
September 18, 2023
|
|
Nitrite Detection at Picogram Level, is it possible?
|
|
4
|
1096
|
September 14, 2023
|
|
Identifying the Risk of Formation of Nitrosamines and Other Potentially Mutagenic Impurities during API Manufacture Using In Silico Risk Assessment -Pub
|
|
0
|
1163
|
June 6, 2023
|
|
A deep dive into historical Ames study data for N-nitrosamine compounds -Pub
|
|
0
|
452
|
September 8, 2023
|
|
A nitrosamine twist
|
|
0
|
473
|
August 24, 2023
|
|
Strategies for Assessing Acceptable Intakes for Novel N-Nitrosamines Derived from Active Pharmaceutical Ingredients
|
|
4
|
677
|
August 23, 2023
|